Serum Levels Of Interleukin-10 Research Articles

Decreased Netrin-1 in Mild Cognitive Impairment and Alzheimer's Disease Patients.

Background and ObjectiveInflammatory mediators are closely associated with the pathogenesis of Alzheimer’s disease (AD) and mild cognitive impairment (MCI). Netrin-1 is an axon guidance protein and despite its capacity to function as a neuroimmune guidance signal, its role in AD or MCI is poorly understood. In addition, the association among netrin-1, cognitive impairment and serum inflammatory cytokines such as interleukin-17 (IL-17) and tumor necrosis (TNF-α) remains unclear. The aim of this study was to determine serum levels of IL-17, TNF-α and netrin-1in a cohort of AD and MCI patients, and to study the relationship between these cytokines and cognitive status, as well as to assess the possible relationships between netrin-1 levels and inflammatory molecules.MethodsSerum concentrations of netrin-1, TNF-α and IL-17 were determined in 20 AD patients, 22 MCI patients and 22 healthy controls using an enzyme-linked immunosorbent assay (ELISA). In addition, neuropsychological evaluations and psychometric assessments were performed in all subjects.ResultsSerum netrin-1 levels were decreased in AD and MCI patients and were positively correlated with Mini Mental State Examination (MMSE) scores. In contrast, serum TNF-α and IL-17 levels were elevated in AD and MCI cohorts and negatively correlated with MMSE scores. Serum netrin-1 levels were inversely related with TNF-α and IL-17 levels in AD, but not MCI, patients.ConclusionBased on the findings reported here, netrin-1 may serve as a marker for the early recognition of dementia and predict cognitive impairment.

Predictive Value of B reg and Serum IL-10 Concentration Levels for Acute ITP Progression to Chronic Phase.

Pediatric immune thrombocytopenia (ITP) is a potentially life threating autoimmune disorder with different responses to therapy and different bleeding phenotypes in critical organs. The molecular basis for the variable response has not yet been fully elucidated. This study was designed to address the predictive value of regulatory B-cell (B reg ) count and interleukin-10 (IL-10) serum levels for acute ITP patients who progress to chronic phase. The present study included 80 children with acute ITP )38 males and 42 females (with median age of 8 years and 40 matched healthy controls. Assessment of B reg (CD19 + CD24 hi CD38 hi ) was carried out by a multicolor flowcytometry, however, IL-10 serum levels were evaluated by enzyme-linked immunosorbent assay. A significant reduction of B reg percentage and a significant increase in serum IL-10 levels were identified in children with acute ITP as compared with controls ( P <0.001 for both). Fourteen ITP patients passed to chronic phase, while 66 patients achieved remission within 6 months. The absolute B reg was significantly lower, while IL-10 was significantly higher in patients with acute ITP who progressed to chronic phase in comparison with acute ITP patients who achieved complete remission. Cox proportional hazards for ITP chronicity revealed that IL-10 OR was 2.46 (confidence interval: 1.42-4.27; P =0.001) and absolute B reg OR was 0.147 (confidence interval: 0.128-0.624; P =0.005) in the peripheral blood. Therefore, they could predict chronicity in ITP cases. Reduced B reg count and elevated IL-10 levels in patients with acute ITP at diagnosis can predict chronicity.

Interleukin-26 is associated with the level of systemic inflammation and lung functions in obese and non-obese moderate-to-severe asthmatic patients.

Obese asthma is a complex syndrome, which includes different phenotypes of disease. At present, these phenotypes only have started to acquire a sufficient understanding. It was suggested that IL-26 is a potential biomarker of disease severity in asthma without signs of Th2-mediated inflammation. In this study, we investigated the serum and exhaled levels of IL-26 and its associations with the level of systemic inflammation, lung functions, and body weight in obese and non-obese moderate-to-severe asthmatic patients MATERIAL AND METHODS: The study included 10 healthy subjects, 10 obese subjects without lung pathologies, 10 non-obese asthmatics (NOA) (BMI 18.5-24.9 kg/m²), and 40 obese asthmatics (OA) (BMI 25.0-49.9 kg/m²). During the visit, patients' examination and spirometry with the bronchodilator reversibility test were conducted, the exhaled breath condensate (EBC) was obtained, and the blood samples were collected. The level of IL-26, interleukin-1β (IL-1β), interleukin-4 (IL-4), interleukin-6 (IL-6), TNF-α, interleukin-10 (IL-10), total and specific immunoglobulin E (IgE), and high sensitive C reactive protein (hs-CRP) were measured using the ELISA kits. Statistical comparison between 2 groups was analyzed using the Mann-Whitney rank-sum test. Chi-square with Yates' correction was used to compare frequencies. Spearman's rank test was used for correlating nonparametric variables. The Receiver Operating Characteristic (ROC) curve and the area under ROC curve (AUC) were used for evaluating the diagnostic power of IL-26 as a possible biomarker. NOA had a reversible airway obstruction with reduced FEV1, FEV1/FVC, FVC 25/75, and positive post-bronchodilator test (PBT), significantly increased serum levels of IL-10, IL-4, and slightly increased IL-26. NOA had significantly increased exhaled IL-26 in comparison with healthy subjects. The obese subjects had a normal ventilatory pattern without airway obstruction, and differences in serum IL-26, IL-10, and IL-4 concentrations in comparison with healthy subjects. Obese subjects had a significant escalation of hs-CRP and no differences in the levels of exhaled IL-26, IL-10, and hs-CRP as compared with healthy subjects. OA had reduced FEV1, FEV1/FVC, and FEV25-75 in comparison with non-obese asthmatics. OA had elevated IL-26, IL-10, IL-4, and hs-CRP concentrations as compared with healthy subjects. These patients had a partial similarity with both non-obese asthmatics (elevated IL-26, IL-10, and IL-4) and obese subjects (elevated, IL-1β, IL-6, TNF-α, hs-CRP). OA had a reduced concentration of exhaled IL-26 in comparison with NOA and elevated exhaled IL-10 in comparison with obese subjects. Furthermore, OA had an increased concentration of IL-1β and TNF-α in comparison with healthy individuals and NOA. Exhaled IL-26 concentration distinguished non-obese asthmatics from healthy subjects, asthmatic patients from non-asthmatics (healthy and obese subjects), all asthmatic patients from non-asthmatics (healthy and obese subjects). Exhaled IL-26 elevated in obese and non-obese moderate-to-severe asthmatic patients. Exhaled IL-26 might be a perspective biomarker in non-obese and obese asthmatics. The obese asthmatic phenotype comprised the combined systemic and local airway inflammation.

Translocator Protein Ligand PIGA1138 Reduces Disease Symptoms and Severity in Experimental Autoimmune Encephalomyelitis Model of Primary Progressive Multiple Sclerosis.

Multiple sclerosis (MS) is an autoimmune and demyelinating disease of the central nervous system (CNS) caused by CNS infiltration of peripheral immune cells, immune-mediated attack of the myelin sheath, neuroinflammation, and/or axonal/neuronal dysfunctions. Some drugs are available to cope with relapsing-remitting MS (RRMS) but there is no therapy for the primary progressive MS (PPMS). Because growing evidence supports a regulatory role of the translocator protein (TSPO) in neuroinflammatory, demyelinating, and neurodegenerative processes, we investigated the therapeutic potential of phenylindolyilglyoxylamydes (PIGAs) TSPO ligands in myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) mice mimicking the human PPMS. MOG-EAE C57Bl/6-mice were treated by TSPO ligands PIGA839, PIGA1138, or the vehicle. Several methods were combined to evaluate PIGAs-TSPO ligand effects on MOG-EAE symptoms, CNS infiltration by immune cells, demyelination, and axonal damages. PIGA1138 (15mg/kg) drastically reduced MOG-EAE mice clinical scores, ameliorated motor dysfunctions assessed with the Catwalk device, and counteracted MOG-EAE-induced demyelination by preserving Myelin basic protein (MBP) expression in the CNS. Furthermore, PIGA1138-treatment prevented EAE-evoked decreased neurofilament-200 expression in spinal and cerebellar axons. Moreover, PIGA1138 inhibited peripheral immune-CD45 + cell infiltration in the CNS, suggesting that it may control inflammatory mechanisms involved in PPMS. Concordantly, PIGA1138 enhanced anti-inflammatory interleukin-10 serum level in MOG-EAE mice. PIGA1138-treatment, which increased neurosteroid allopregnanolone production, ameliorated all pathological biomarkers, while PIGA839, unable to activate neurosteroidogenesis in vivo, exerted only moderate/partial effects in MOG-EAE mice. Altogether, our results suggest that PIGA1138-based treatment may represent an interesting possibility to be explored for the innovation of effective therapies against PPMS.

Disturbance in Serum Levels of IL-17 and TGF-β1 and in Gene Expression of ROR-γt and FOX-P3 Is Associated with Pathogenicity of Systematic Lupus Erythematosus.

To investigate the disturbance in serum levels of interleukin-17 (IL-17) and transforming growth factor-beta1 (TGF-β1) and gene expression of retinoic acid-related orphan receptor-gamma t (ROR-γt) and forkhead box-P3 (FOX-P3) in patients with systemic lupus erythematosus (SLE) and to study their association with disease pathogenicity and activity. Newly diagnosed active patients with SLE (n=88) and healthy volunteers (n=70) were included. Serum IL-17 and TGF-β1 were measured using enzyme-linked immunosorbent assay. Gene-expression profiles of ROR-γt and FOX-P3 were screened using real-time polymerase chain reaction. The IL-17/TGF-β1 and ROR-γt/FOX-P3 levels were also calculated. The mean age of the patients was 30.96±8.25 years; they were 82 women and 6 men. Of the patients, 11.4% manifested mild disease while 88.6% had severe disease. The serum level of TGF-β1 was significantly lower (70.2±34.9 vs. 200.23±124.77 pg/ml), while both IL-17 (614.7±317.5 vs. 279.76±110.65 pg/ml) and IL-17/TGF-β1 (18.5±30.1 vs. 1.66±0.9) levels were significantly higher, in patients than in controls (p&lt;0.0001). The gene-expression level of FOX-P3 (0.6±0.8 vs. 13.68±39.35) was reported to be lower, while ROR-γt (3.9±3.5 vs. 1.99±2.09) and ROR-γt/FOX-P3 (18.6±21.1 vs. 7.63±17.19) levels were significantly higher, in patients than in controls (p&lt;0.0001). Disturbance in serum levels of IL-17 and TGF-β1 in T helper-17 and T-regulatory cells proliferation was highlighted through an imbalance in the gene expression of FOX-P3 and ROR-γt, as both are signature genes for the two cell types, respectively. These findings underscore the critical role of IL-17 and TGF-β1 in SLE development, rendering them potential targets for developing novel immunotherapeutic strategies.

Immunomodulatory Effects of Bio-Clean II on Some Inflammatory Cytokines in Rats Exposed to Purified Bacterial Lipopolysaccharide

Bacterial inflammatory diseases have continued to be a major threat to public health. The aim of this study is to determine the effects of Bio-Clean II on serum levels of some selected cytokines in rats exposed to purified bacterial lipopolysaccharide (LPS). A total of 36 male Wistar rats weighing 150g±50g (mean±SD) were purchased and randomly assigned to six (6) groups of 6 rats each. Group 1, 2, 3, 5 and 6 were induced with a single dose of 5mg/Kg of purified LPS® (E.coli 0127:B8, Sigma-Aldrich, St. Louis, USA), administered through intraperitoneal route using 1ml sterile needle and syringe, except for group 4 which served as the zero control (given water and feed only throughout the experiment). Group 1 served as the inflammation control. Group 2 which served as the positive control received 50 mg diclofenac/kg [bid] and 500 mg ciprofloxacin/kg [bid] (positive control) in place of the Bio-Clean. Group 3 which served as the negative control received sterile phosphate buffer saline (PBS). While rats in group 5 and group 6 were treated orally with the herbal remedy “Bio-Clean II” for 7 days and 14 days, respectively. After which, the rats were sacrificed and a cardiac blood specimen was taken from each rat by terminal bleeding from the heart. The serum levels of Interleukin-6 (IL-6), Interleukin-10 (IL-10), Interferon-Gamma (IFN-γ), and Tissue Necrosis Factor-Alpha (TNF-α) were determined using ELISA technique. The outcome of this investigation shows that treatment with the Bio-Clean II resulted in a significant decrease (p=0.000*) in the serum level of IL-6, IFN-γ and TNF-α, but a significant (p=0.000*) increase in the serum level of IL-10 (in a duration-dependent manner) in rats exposed to LPS when compared to the inflammation control group. The outcome of this study suggests that Bio-Clean could find some use in the future for the alleviation of bacterial inflammatory diseases through modulations of host inflammatory responses to pathogens.

Molecular mechanism of astragaloside Ⅳ against atherosclerosis by regulating miR-17-5p and PCSK9/VLDLR signal pathway

This study explores the regulatory effect of astragaloside Ⅳ on miR-17-5 p and its downstream proprotein convertase subtillisin/kexin type 9(PCSK9)/very low density lipoprotein receptor(VLDLR) signal pathway, aiming at elucidating the mechanism of astragaloside Ⅳ against atherosclerosis(AS). In cell experiment, oxidized low-density lipoprotein(ox-LDL) was used for endothelial cell injury modeling with vascular smooth muscle cells(VSMCs). Then cells were classified into the model group, miR-17-5 p inhibitor group, blank serum group, and astragaloside Ⅳ-containing serum group based on the invention. Afterward, cell viability and the expression of miR-17-5 p, VLDLR, and PCSK9 mRNA and protein in cells in each group were detected. In animal experiment, 15 C57 BL/6 mice were used as the control group, and 45 ApoE~(-/-) mice were classified into the model group, miR-17-5 p inhibitor group, and astragaloside Ⅳ group, with 15 mice in each group. After 8 weeks of intervention, the peripheral serum levels of interleukin-6(IL-6), interleukin-10(IL-10), and tumor necrosis factor-α(TNF-α), and the expression of miR-17-5 p, VLDLR, and PCSK9 mRNA in the aorta of mice were detected. The pathological changes of mice in each group were observed. According to the cell experiment, VSMC viability in the miR-17-5 p inhibitor group and the astragaloside Ⅳ-containing serum group was higher than that in the model group(P&lt;0.05). The mRNA and protein expression of miR-17-5 p and VLDLR in VSMCs in the miR-17-5 p inhibitor group and the astragaloside Ⅳ-containing serum group was lower than that in the model group(P&lt;0.05), but the mRNA and protein expression of PCSK9 was higher than that in the model group(P&lt;0.05). As for the animal experiment, the levels of IL-6 and TNF-α in the peripheral serum of the miR-17-5 p inhibitor group and the astragaloside Ⅳ group were lower(P&lt;0.05) and the serum level of IL-10 was higher(P&lt;0.05) than that of the model group. The mRNA expression of miR-17-5 p and VLDLR in the aorta in the miR-17-5 p inhibitor group and the astragaloside Ⅳ group was lower(P&lt;0.05), and PCSK9 mRNA expression was higher(P&lt;0.05) than that in the model group. Pathological observation showed mild AS in the miR-17-5 p inhibitor group and the astragaloside Ⅳ group. In summary, astragaloside Ⅳ can prevent the occurrence and development of AS. The mechanism is that it performs targeted regulation of miR-17-5 p, further affecting the PCSK9/VLDLR signal pathway, inhibiting vascular inflammation, and thus alleviating endothelial cell injury.

Serum Levels of Interleukin-10 and D-Dimer as Biomarkers of Coronavirus Disease

Serum Levels of Interleukin-10 and D-Dimer as Biomarkers of Coronavirus Disease

Study of the Value of Interleukin-35 Combined with Lymphocyte/Monocyte Ratio in the Prognosis of Patients with Sepsis

To investigate the value and role of serum interleukin-35 and lymphocyte/monocyte ratio for the prognostic assessment of sepsis cases is the main objective of the study. 78 sepsis patients sera was collected from October 2019 to October 2021 in our intensive care unit and were classified as survival (n=45) and death (n=33) groups based on their prognosis. In addition, 50 normal healthy subjects were also enrolled as control. Then, interleukin-35 contents in serum and lymphocyte/monocyte ratio of different groups were measured separately. We also analyzed the association of serum interleukin-35 with lymphocyte/ monocyte ratio among 78 sepsis cases and performed survival analysis on the serum interleukin-35 levels. Interleukin-35 expression of survival group increased relative to normal group, with no significant difference (p>0.05). Death group had markedly increased interleukin-35 expression compared with survival and normal groups (p<0.05) and difference in the lymphocyte/monocyte ratio values between death and survival groups was of no statistical significance (p>0.05). Interleukin-35 was not evidently correlated with lymphocyte/monocyte ratio (p>0.05). Survival analysis showed that sepsis cases with high interleukin-35 expression had significantly decreased survival, relative to low interleukin-35 expression (p<0.05). Serum interleukin-35 is the prognostic biomarker for sepsis cases and high interleukin-35 expression during early sepsis may indicate poor prognosis and the concentration of interleukin-35 levels has a high prognostic assessment value for sepsis survival compared with lymphocyte/monocyte ratio levels.

DIFFERENTIAL PROFILE OF PRO-INFLAMMATSORY / ANTI-INFLAMMATORY CYTOKINES AND MALONDIALDEHYDE IN PATIENTS WITH ALCOtHOL-INDUCED OR OBESITY OR MIXED INJURY

Dysregulation of pro-inflammatory/anti-inflammatory cytokines and oxidative stress markers has been reported in Non-Alcoholic Steatohepatitis (NASH) and alcoholic steatohepatitis (ASH); however, in the disease recently known, as Both Alcoholic and Non-Alcoholic SteatoHepatitis (BASH) that meets the criteria of ASH and NASH have not been described. The objective was to evaluate the influence of alcohol and obesity on a differential profile of cytokines and malondialdehyde (MDA) in patients with these etiologies. Cross-sectional, prospective, observational study. Patients from the “Dr. José E. González” from March 2019-March 2020, with a diagnosis of ASH (alcohol consumption ≥ 5 years, 30 g/day for men and 20 g/day for women), NASH (demonstrated by ultrasound, FibroScan or FibroMax) and BASH (ASH and NASH criteria). The serum cytokines interleukin-8 (IL-8), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β), interleukin-10 (IL-10) and malondialdehyde (MDA) were determined. The protocol was approved by the ethics committee with registration MI19-000016.One-way analysis of variance was performed with Kruskal-Wallis and Dunn's post hoc. The results were expressed as median (interquartile range). The analysis was performed using Graph Pad Prism (v. 7.04, San Diego, CA, USA). A value of p <0.05 was considered significant. The patients were: 34 BASH, 43 NASH and 35 ASH. The severity of the patients with respect to clinical and biochemical parameters in increasing order was NASH <BASH <ASH. It was observed in increasing order that the levels of the cytokines IL-8, IL-6, IL-10 were: NASH <BASH <ASH; TNF-α levels were: BASH <NASH <ASH; IL-1β levels show no significant difference between groups (Figure). The BASH group showed higher concentration levels of MDA [20.00 (9.00-30.50) pg/mL] with significant difference (p = 0.0434) compared to NASH [14.00 (3.00-19.00) pg/mL], but not with ASH (Figure). Serum levels of IL-6 (A; p <0.0001), TNF-α (B; p =0.0014), IL-8 (C; p <0.0001), IL-10 (D; p <0.0001) and IL-1β (E; Not significant) in the different study groups. In ASH and NASH, common pathogenetic mechanisms mediated by pro-inflammatory. The authors declare that there is no conflict of interest.

Serum interleukin 15 level may serve as a new marker for alopecia areata

Background Alopecia areata (AA) is an autoimmune form of nonscarring hair loss that may affect any hair-bearing area. It is one of the most common forms of hair loss seen by dermatologists. The serum level of interleukin 15 (IL-15) is elevated in AA; subsequently, IL-15 limits the suppressive effect of regulatory T cells and activates CD8+NKG2D+ T cells to attack the cells of the hair bulb and initiate AA. Inhibiting IL-15 activity might be a breaking new therapeutic strategy in the treatment of AA. Patients and methods Serum IL-15 levels were measured by an enzyme-linked immunosorbent assay for 30 patients with active AA (group A), 30 patients with stable AA (group B), and 60 healthy participants of age-matched and sex-matched controls (group C). Results Serum levels of IL-15 were significantly increased in patients with AA and showed a significant positive correlation with severity (Severity of Alopecia Tool score) and activity of the disease. Receiver operating characteristics curve detected the validity of serum IL-15 in differentiating patients with AA from controls. The best cutoff point for IL-15 was determined to be more than or equal to 7.66 pg/ml, which was able to predict AA with 98.3 sensitivity and 100% specificity. Receiver operating characteristics curve of IL-15 was also conducted to evaluate the sensitivity and specificity of serum IL-15 as a diagnostic index for discrimination between active and stable AA cases, and the best cutoff point for IL-15 was determined to be more than or equal to 21.2 pg/ml, which was able to predict active AA, with 93.3 sensitivity and 100% specificity. Higher IL-15 levels were associated with prediction of severity and activity of AA. Conclusion Serum IL-15 may represent a new marker for AA diagnosis as well as a predictor of the disease severity and activity.

Studying the Effect of Garlic Consumption and Endurance Training on Serum Levels of Some Pro-and Anti-inflammatory Cytokines in Female Mice with Breast Cancer - A Randomized Trial.

Background:This study aimed to determine the effect of garlic consumption and endurance training on the serum levels of some pro-inflammatory and anti-inflammatory cytokines in female mice with breast cancer.Methods:This study is an experimental research randomly conducted on 32 female BALB/c mice divided into 4 equal groups (N = 8), including: Cancer Control (CC), Garlic Supplementation (GS), Endurance Training (ET), Endurance Training + Garlic Supplementation (ET + GS). One million cancerous cells were injected to all mice's upper right thigh using the subcutaneous injection method. Exercise groups performed endurance training for 8 weeks (5 days a week.(Garlic supplement groups received 1 ml of the garlic extract orally per kilogram of body weight. The control groups -were not given any task, activity or exercise during the research. At the end of the research, all the mice were anesthetized, and their blood samples were collected.Results:The period of 8-week simultaneous endurance exercise and consumption of garlic supplement significantly decreased the serum level of interleukin-6 (F = 75 P = 0.00), interleukin-8 (F = 97.9 P = 0.00), and interleukin-17 (F = 95.7 P = 0.00), and increased the serum level of interleukin-10 (F = 50.4 P = 0.00).Conclusions:Along with other existing methods, reduction of inflammatory factors, endurance exercises and consumption of garlic supplement have been proved to be an extremely effective treatment for breast cancer patients.

1335. High Serum Levels of Interleukin-10 as a Predictor Factor of In-Hospital Mortality in COVID-19 Patients

BackgroundSince the spread of SARS-CoV-2 worldwide, there has been the need for scores and biomarkers to identify patients at risk of died or requiring admission to the intensive care units (ICU) admission. Interleukin-10 (IL-10) is released as a response to the infection, stimulating inflammatory pathways in the acute phase response. Thus, previous studies have shown that high serum concentrations IL-10 can be identify patients with severe community acquired pneumonia (CAP). Nevertheless, there is a lack of information regarding the capacity of IL-10 to identify severe COVID-19. Thus, the aim of this study was to determine the capacity of IL-10 as a prediction factor for mortality in hospital admitted patients with COVID-19 compared with CAP patients.MethodsA prospective observational study was carried out at the Clinica Universidad de La Sabana, Colombia. Patients older than 18 years and old, hospitalized due to COVID 19 or CAP, were included. Patients were stratified into COVID-19 and non-COVID-19 patients. IL-10 levels were quantified in serum samples using the LUMINEX technology. Serum samples were collected within the first 24 hours of hospital admission. Afterward, concentrations of interleukinwere statistically compared among groups. ROC curves were calculated. ResultsA total of 88 patients with CAP and 152 patients with COVID-19 were enrolled in the study. The median [with IQR] serum concentration of IL-10 were higher in those patients who died (81.1 [30.7-148.9] vs 18.8 [8.3-48.4] p-value < 0.0001). Then, comparing the study group, the median concentration of IL-10 levels among patients deceased by COVID-19 were higher than patients those who survived (85.1 [40-149.8] vs 32.4 [13.9-56.7] p-value < 0.001). In addition, IL-10 levels were higher in patients who survived COVID-19 compared with those who survived CAP (32.4 [13.9-56.7] vs 10.6 [4.9-18] p-value < 0.0001). The area under curve (AUC) ROC of IL-10 to predict mortality risk was 0.754 for all cohort. DeLong′s test comparing ROC curves in COVID-19 and CAP patients had a p= 0.744. ConclusionHigh serum levels of IL-10 are a good predictor of in-hospital mortality among COVID-19 patients. However, this risk association was not observed in CAP patients. Further studies are needed. Disclosures All Authors: No reported disclosures

Serum interleukin-17 and estradiol levels in postmenopausal women in relation to osteoporosis

BackgroundIn post-menopausal women, estrogen deficiency leads to instability between bone formation and resorption which is regulated by osteoclastogenic cytokines leading to resorption. Interleukin-17 (IL-17) a proinflammatory cytokine has been found as an important regulator of osteoclast-genesis induced by estrogen deficiency in favor of bone loss in animal studies.The study aimed to evaluate levels of IL-17 and estrogen (E2) in relation to bone mineral density (BMD) and risk of fracture in postmenopausal women with and without osteoporosis.ResultsIL-17 levels were significantly higher and E2 levels were significantly lower in the osteoporotic group compared to the non-osteoporotic group (P value ≤ 0.01). There was a highly significant difference in DEXA score and FRAX index between two groups: with higher values of FRAX and lower values of DEXA score among osteoporotic group (P value ≤ 0.01). IL-17 was inversely correlated to estrogen level and highly significant negative correlation with DEXA as well as a highly significant positive one with FRAX index. IL-17 serum level was able to diagnose osteoporosis at a cutoff level of > 80 pg/mL with 100% sensitivity, 100% specificity, 100% positive predictive value (PPV), and 100% negative predictive value (NPV).ConclusionsSerum IL-17 was significantly elevated in osteoporotic postmenopausal women when compared to healthy postmenopausal ones and was inversely correlated with estrogen level and DEXA.

The association between elevated serum interleukin-22 and the clinical diagnosis of axial spondyloarthritis: A retrospective study.

There is an unmet need for a reliable biomarker for the differentiation of axial spondyloarthritis (AxSpA) from its mimickers. Serum levels of interleukin-22 (IL-22) have previously been found to be significantly elevated in patients with AxSpA compared with healthy individuals or persons with osteoarthritis. Consecutive patients with established or suspected AxSpA were enrolled. The clinical data, as well as results of laboratory and imaging studies, were acquired from patients' charts. The final diagnosis of definite or probable SpA, or an alternative diagnosis, was determined, and the serum levels of IL-22 were examined by enzyme-linked immunosorbent immunoassay. Interleukin-22 levels were significantly higher in patients with definite AxSpA (29 patients) compared with patients with alternative diagnoses (14 patients) and healthy volunteers (16 individuals; P<0.001 for both comparisons). The sensitivity and specificity of the serum IL-22 for the AxSpA diagnosis were 0.68 (95% CI 0.49-0.84) and 0.86 (95% CI 0.68-0.95), respectively, for the cut-off value of 5pg/mL. In patients with AxSpA, serum IL-22 levels did not correlate with modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS), or serum C-reactive protein. Serum IL-22 levels are elevated in patients with the clinical diagnosis of AxSpA and can potentially serve as an independent biomarker for the differentiation of AxSpA from its non-inflammatory mimickers.

Diagnostic and Predictive Utility of Serum Interleukin-37 in Rheumatoid Arthritis: A Case-Control Study

Background: Rheumatoid arthritis is the most common cause of inflammatory polyarthritis. Interleukin‐37 (IL-37) has been found to play an important regulatory role in the development of inflammatory diseases. Objectives: To assess serum IL-37 level in rheumatoid arthritis (RA) patients compared to controls, to evaluate its diagnostic and predictive utility in RA patients and to investigate IL-37 level correlation with demographic and clinical characteristics of RA. Methods: Eighty subjects, 40 RA patients aged between 23-63 years and 40 healthy controls aged between 28-67 years were evaluated. An enzyme-linked immunosorbent assay (ELISA) was used to analyze the serum IL-37 levels. Results: Serum IL-37 was significantly higher in RA patients compared to healthy controls. At optimum cut off value of &gt;58.275 pg/ml, serum IL-37 had 100% accuracy, positive predictive value, negative predictive value, sensitivity, and specificity. Serum IL‐37 level was not significantly related to Disease Activity Score of 28 joints‐erythrocyte sedimentation rate (DAS28‐ESR), also not correlated with C-reactive protein(CRP), rheumatoid factor(RF) and anti-cyclic citrullinated peptide antibody (Anti-CCP). Also there was no correlation between the level of IL-37 and treatment. Conclusions: IL-37 was significantly higher in RA patients compared to healthy controls with a high diagnostic and predictive ability, and may be a potential biomarker for diagnosis and prediction of RA.

Evaluation of serum levels of IL-6, IL-10, and TNF-a in alopecia areata patients: A systematic review and meta-analysis

Background: The role of pro and anti-inflammatory cytokines in autoimmune and inflammatory disorders has always been discussed; several studies have assayed serum levels of Interleukin-6 (IL-6), Tumor Necrosis Factor-α (TNF-α), and Interleukin-10 (IL-10) in alopecia areata (AA) patients. Determining the cytokine profile of AA patients will help us understand the role of the immune system in the pathogenesis of AA. Due to a lack of comprehensive studies in this regard, we have performed this meta-analysis to evaluate previously mentioned cytokines in AA patients. Methods: We explored PubMed, Scopus, web of science, and ScienceDirect databases for research without a limited start date until May 2021. A number of 1098 studies were found in the initial database search and reference lists of relevant studies; 16 studies were finally included in the meta-analysis. Differences in the levels of IL-6, TNF-α, and IL-10 in sera of controls and patients were pooled as standardized mean differences. A random-effects model was used in this study. Begg's and Egger's tests were carried out to investigate publication bias. Results: 16 studies were included. This study found significantly elevated levels of IL-6 in AA patients compared to healthy subjects (SMD = 1.57, 95% CI 0.17 to 2.97). The levels of TNF-α were also significantly higher in the serum of AA patients (SMD = 2.05, 95% CI 0.98 to 3.13). Though IL-10 levels were lower in serum of AA patients, this difference was not significant (SMD = -0.22, 95% CI -0.95 to 0.50). Conclusion: According to the crucial role of cytokines in autoimmunity, alternation in the serum levels of cytokines in AA patients was not unexpected; our study shows that cytokines might have an essential role in the pathogenesis of AA, though further studies are needed to clarify the exact role of cytokines in the emergence and persistence of AA.

Galectin-3 and Interleukin-17: A potential role in the pathogenesis of human papilloma virus infection.

In many cases, human papillomavirus (HPV) infection is self-limiting, as innate and adaptive cell-mediated immunity is needed for infection elimination; however, the inability of the immune system in some patients to clear the infection is a matter of debate. The interleukin-17 (IL-17) family cytokines play an important protective role in host immune response to infections, through maintaining immunity against specific pathogens, induction of antimicrobial proteins, and recruitment of neutrophils to sites of invasion. Galectin-3 (Gal-3) may be considered as a marker of viral infection as many studies reported its increased serum level in viral infections. To evaluate levels of serum Gal-3 and IL-17 in patients with verrucas and to explore the potential role of these markers in the pathogenesis of the disease. Fifty patients suffering from HPV Infection, and fifty healthy controls were included in this study. Serum levels of Gal-3 and IL-17 were assessed using enzyme-linked immunosorbent assay. The patients' serum Gal-3 was significantly higher, while IL-17 was significantly lower than that of the healthy controls (p-value<0.001). Moreover, a statistically significant positive correlation was found between Gal-3 serum level and disease duration and number of warts. Significant negative correlation exists between IL-17 and Gal-3 levels. Our results indicate a potential role of both IL-17 and Gal-3 in the pathogenesis of warts and open a new opportunity in targeting these markers in the future in treating warts.

Lack of Association between Serum Interleukin-23 and Interleukin-27 Levels and Disease Activity in Patients with Active Systemic Lupus Erythematosus.

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease characterized by the production of multiple autoantibodies, resulting in tissue and organ damage. Recent studies have revealed that interleukin-23 (IL-23) and interleukin-27 (IL-27) may be therapeutically relevant in selected SLE manifestations. This study aimed to identify associations between serum IL-27 and IL-23 levels and disease activity in Polish patients with different manifestations of SLE: neuropsychiatric lupus (NPSLE), and lupus nephritis (LN). Associations between interleukin levels and oligo-specific antibodies against double-stranded DNA (dsDNA), dose of glucocorticoids, and type of treatment were also analyzed. An enzyme-linked immunosorbent assay was used to assess anti-dsDNA antibodies and analyze the serum concentration of IL-27 and IL-23 from 72 patients aged 19–74 years with confirmed active SLE. Disease activity was measured using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2-K). No significant correlations between interleukin levels and SLEDAI score, anti-dsDNA, corticosteroid dose, or type of treatment were noted. Patients with NPSLE and LN presented the highest median scores of SLEDAI.

Interleukin 37 Levels in Relation to Serum Vitamin D Levels Among Ain Shams University Medical Students

Abstract Background The extraskeletal role of vitamin D is being increasingly recognized. This has important clinical implications, as vitamin D deficiency has reached epidemic proportions worldwide. Vitamin D has proposed anti-inflammatory properties as recent data suggests that low vitamin D concentrations are associated with increased levels of inflammatory markers. Interleukin-37(IL-37) is an IL1 family cytokine discovered in recent years and has 5 different isoforms. As an immunosuppressive factor, IL-37 can suppress excessive immune response .IL37 plays a role in protecting the body against endotoxin shock, ischemia reperfusion injury, autoimmune diseases, and cardiovascular diseases. In addition, IL-37 has a potential antitumor effect. IL-37 and its receptors may serve as novel targets for the study, diagnosis, and treatment of immune-related diseases and tumors. Aim of the Work The aim of this study is to determine the relation between the level of interleukin-37 and 25-hydroxy Vitamin D among Ain Shams University medical students. Subjects and Methods The study was conducted at Clinical Pathology Department, Ain Shams University Hospitals. Ninety individuals, from medical students of Ain Shams University who participated in the Nutritional Assessment of Ain Shams University Medical Students (NAMESASU) Project, were selected to be in the study. The study included 2 groups: Group I: included 45 subjects selected from the NAMES-ASU project with deficient vitamin D serum levels. Group II: included 45 subjects selected from the NAMES-ASU project with sufficient vitamin D serum levels. Results There was a highly significant difference between the two groups regarding vitamin D levels. Serum IL-37 levels were significantly higher in group I subjects compared to group II subjects. No significant difference was observed between group I and group II regarding BMI, BFM, PBF and hsCRP. No significant difference was observed between the two subgroups regarding IL-37 levels and hsCRP levels. A highly significant negative correlation was observed between vitamin D levels and IL-37. A significant negative correlation was observed between hsCRP and vitamin D levels. However, no correlation was observed between hsCRP and IL-37 levels. Conclusion Data from our study showed that present study denote that in case of vitamin D deficiency, irrespective of BMI, a subclinical state of inflammation may be present as reflected by the increased hsCRP levels and this state of inflammation might induce an increase in IL-37, an anti-inflammatory cytokine, in an attempt to reduce the inflammation.